BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30871885)

  • 1. Post-operative wall shear stress in the superior mesenteric artery: Biomarker of long term outcome in patients with residual disease after incomplete cytoreductive surgery for pseudomyxoma peritonei.
    Barral M; El Sanharawi I; Eveno C; Dohan A; Launay JM; Lo Dico R; Pocard M; Bonnin P
    Eur J Surg Oncol; 2019 Sep; 45(9):1727-1733. PubMed ID: 30871885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of clinical outcome using blood flow volume in the superior mesenteric artery in patients with pseudomyxoma peritonei treated by cytoreductive surgery.
    Dohan A; Barral M; Eveno C; Lo Dico R; Kaci R; Pasteur-Rousseau A; Soyer P; Pocard M; Bonnin P
    Eur J Surg Oncol; 2017 Oct; 43(10):1932-1938. PubMed ID: 28587731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Flow and Shear Stress Allow Monitoring of Progression and Prognosis of Tumor Diseases.
    Barral M; El-Sanharawi I; Dohan A; Sebuhyan M; Guedon A; Delarue A; Boutigny A; Mohamedi N; Magnan B; Kemel S; Ketfi C; Kubis N; Bisdorff-Bresson A; Pocard M; Bonnin P
    Front Physiol; 2021; 12():693052. PubMed ID: 34413786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should total gastrectomy and total colectomy be considered for selected patients with severe tumor burden of pseudomyxoma peritonei in cytoreductive surgery?
    Liu Y; Mizumoto A; Ishibashi H; Takeshita K; Hirano M; Ichinose M; Takegawa S; Yonemura Y
    Eur J Surg Oncol; 2016 Jul; 42(7):1018-23. PubMed ID: 27241925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 7. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
    Baratti D; Kusamura S; Milione M; Pietrantonio F; Caporale M; Guaglio M; Deraco M
    Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
    Bjersand K; Mahteme H; Sundström Poromaa I; Andréasson H; Graf W; Larsson R; Nygren P
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S810-6. PubMed ID: 26193962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin.
    Rangarajan K; Chandrakumaran K; Dayal S; Mohamed F; Moran BJ; Cecil TD
    Int J Hyperthermia; 2018 Aug; 34(5):559-563. PubMed ID: 29063804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
    J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
    Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
    Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei.
    Benhaim L; Faron M; Gelli M; Sourrouille I; Honoré C; Delhorme JB; Elias D; Goere D
    Surg Oncol; 2019 Jun; 29():78-83. PubMed ID: 31196498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report.
    Thorgersen EB; Melum E; Folseraas T; Larsen SG; Line PD
    World J Surg Oncol; 2018 Sep; 16(1):180. PubMed ID: 30185175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
    Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre- and post-operative antibiotics in conjunction with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) should be considered for pseudomyxoma peritonei (PMP) treatment.
    Merrell DS; McAvoy TJ; King MC; Sittig M; Millar EV; Nieroda C; Metcalf JL; Blum FC; Testerman TL; Sardi A
    Eur J Surg Oncol; 2019 Sep; 45(9):1723-1726. PubMed ID: 30770164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
    Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery plus perioperative intraperitoneal chemotherapy in pseudomyxoma peritonei: aspects of the learning curve.
    Andréasson H; Lorant T; Påhlman L; Graf W; Mahteme H
    Eur J Surg Oncol; 2014 Aug; 40(8):930-6. PubMed ID: 24656455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome and surgical strategy in critical sites in cases of psuedomyxoma peritonei.
    Mahmoud AM; Hussein MM; Moneer MM
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):249-255. PubMed ID: 27658904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.